P-15 vs Palifermin
Head-to-head comparison of P-15 (Synthetic Collagen Type I Cell-Binding Peptide (P-15)) and Palifermin (Recombinant Human Keratinocyte Growth Factor (KGF, FGF7)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | P-15 | Palifermin |
|---|---|---|
| Category | Recovery & Healing | Recovery & Healing |
| Full Name | Synthetic Collagen Type I Cell-Binding Peptide (P-15) | Recombinant Human Keratinocyte Growth Factor (KGF, FGF7) |
| Molecular Weight | 1500 Da | 16.3 kDa |
| Half-Life | N/A | 4–6 hours |
| Amino Acids | 15 | 140 |
| Typical Dose | device-dependent local loading | 60 µg/kg/day |
| Route | Local/Implant | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 150 | 250 |
| Research Status | Clinical | Clinical |
P-15 Benefits
- ✓improves osteoblast attachment
- ✓supports scaffold osteointegration
- ✓enhances bone fill
- ✓may aid periodontal regeneration
Palifermin Benefits
- ✓epithelial protection
- ✓mucosal regeneration
- ✓barrier restoration
- ✓reduced inflammatory injury
P-15 Dosing
embedded in scaffold or graft material|local application|single procedural exposure
Palifermin Dosing
IV 60 µg/kg/day for 3 days before and 3 days after insult|research protocols vary|short courses only
P-15 Side Effects
- ⚠local irritation
- ⚠inflammation
- ⚠hypersensitivity
Palifermin Side Effects
- ⚠rash
- ⚠taste changes
- ⚠edema
- ⚠arthralgia
Research Overview
P-15
P-15 is a real literature-backed peptide used to improve biomaterial performance in bone repair settings. Most of the evidence is device- or scaffold-based rather than as a free systemic peptide.
Palifermin
Palifermin is clinically established for mucosal protection and has been studied for epithelial repair in other tissues. The strongest evidence is for epithelial resilience and regeneration rather than direct dermal remodeling.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.